Last 12 months
Inside the activity.
1 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 1 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2019 Filed Jul 5, 2019 20:51 UTC |
Karp DanielEVP, Corporate Development
|
Tax withholdingCommon Stock | 58 | $236.37 | $13,709.46 |
DisclosureSEC source: 0001127602-19-024060 · form4.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264.387 Read SEC document |
| July 02, 2019 Filed Jul 5, 2019 20:51 UTC |
Karp DanielEVP, Corporate Development
|
Exercise / conversionCommon Stock | 196 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-024060 · form4.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · EVP, Corporate Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322.387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20.653 shares acquired under the Biogen Inc. Employee Stock Purchase Plan on 9/28/2018. F2 · balance_after: Includes 23.683 shares acquired under the Biogen Inc. Employee Stock Purchase Plan on 12/31/2019. F3 · balance_after: Includes 82.051 shares acquired under the Biogen Inc. Employee Stock Purchase Plan on 3/29/2019. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 22:02 UTC |
Mantas Jesus BDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022435 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 22:00 UTC |
SHERWIN STEPHEN ADirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022431 · form4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,319 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 22:01 UTC |
HAWKINS WILLIAM ADirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022434 · form4.xml · nonDerivative · entry 1 HAWKINS WILLIAM A · CIK 0001106508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:59 UTC |
SCHENK LYNNDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022429 · form4.xml · nonDerivative · entry 1 SCHENK LYNN · CIK 0001236534 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,032 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:57 UTC |
Rowinsky Eric KDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022427 · form4.xml · nonDerivative · entry 1 Rowinsky Eric K · CIK 0001318886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,179 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:55 UTC |
Posner Brian SDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022426 · form4.xml · nonDerivative · entry 1 Posner Brian S · CIK 0001372455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:54 UTC |
PAPADOPOULOS STELIOSDirector
|
GrantCommon Stock | 1,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022424 · form4.xml · nonDerivative · entry 1 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,095 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:52 UTC |
PANGIA ROBERT WDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022422 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,742 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:51 UTC |
Mulligan RichardDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022420 · form4.xml · nonDerivative · entry 1 Mulligan Richard · CIK 0001376247 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,064 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:50 UTC |
LEAMING NANCYDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022418 · form4.xml · nonDerivative · entry 1 LEAMING NANCY · CIK 0001265751 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,098 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:48 UTC |
DORSA CAROLINEDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022416 · form4.xml · nonDerivative · entry 1 DORSA CAROLINE · CIK 0001181174 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,207 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 21:47 UTC |
DENNER ALEXANDER JDirector
|
GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022414 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,064 Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC |
Ehlers Michael DEVP, Research and Development
|
OtherRestricted Stock Unit · Derivative | 1,376 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · derivative · entry 5 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,376 shares Expires 2019-06-01 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC |
Ehlers Michael DEVP, Research and Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,126 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · derivative · entry 4 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,376 Underlying: Common Stock · 1,126 shares Expires 2019-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC |
Ehlers Michael DEVP, Research and Development
|
Tax withholdingCommon Stock | 500 | $219.29 | $109,645.00 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · nonDerivative · entry 3 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,025.222 Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC |
Ehlers Michael DEVP, Research and Development
|
Exercise / conversionCommon Stock | 1,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · nonDerivative · entry 2 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,525.222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 20:56 UTC |
Ehlers Michael DEVP, Research and Development
|
Tax withholdingCommon Stock | 460 | $219.29 | $100,873.40 |
DisclosureSEC source: 0001127602-19-020742 · form4.xml · nonDerivative · entry 1 Ehlers Michael D · CIK 0001674364 · EVP, Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,399.222 F1 · balance_after: Includes 82.051 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2019. Read SEC document |
| May 02, 2019 Filed May 2, 2019 21:06 UTC |
DENNER ALEXANDER JDirector
|
PurchaseCommon Stock | 38,000 | $231.24 | $8,787,120.00 |
DisclosureSEC source: 0001127602-19-017009 · form4.xml · nonDerivative · entry 3 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 643,000 F1 · ownership.nature: Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein. F2 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the "Sarissa Funds"). Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:20 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
OtherRestricted Stock Unit · Derivative | 1,772 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017441 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,772 shares Expires 2019-05-02 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:20 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,480 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017441 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,772 Underlying: Common Stock · 1,480 shares Expires 2019-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:20 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 658 | $230.52 | $151,682.16 |
DisclosureSEC source: 0001127602-19-017441 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,829.321 Read SEC document |
| May 02, 2019 Filed May 6, 2019 20:20 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 1,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-017441 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,487.321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:06 UTC |
DENNER ALEXANDER JDirector
|
PurchaseCommon Stock | 30,000 | $229.46 | $6,883,800.00 |
DisclosureSEC source: 0001127602-19-017009 · form4.xml · nonDerivative · entry 2 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 605,000 F1 · ownership.nature: Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein. F2 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the "Sarissa Funds"). Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Read SEC document |
| May 01, 2019 Filed May 2, 2019 20:30 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
PurchaseCommon Stock | 4,351 | $231.48 | $1,007,169.48 |
DisclosureSEC source: 0001127602-19-016956 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,007.321 F1 · price: This represents the weighted average price for shares purchased at a range between $231.47 (low) and $232.06 (high). F2 · price: Full information regarding the number of shares purchased at each separate price will be provided to the SEC staff, the issuer or any security holder of the issuer, upon their request. F3 · balance_after: Includes 82.051 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2019. Read SEC document |
| April 30, 2019 Filed May 2, 2019 21:06 UTC |
DENNER ALEXANDER JDirector
|
PurchaseCommon Stock | 50,342 | $229.25 | $11,540,903.50 |
DisclosureSEC source: 0001127602-19-017009 · form4.xml · nonDerivative · entry 1 DENNER ALEXANDER J · CIK 0001361754 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 575,000 F1 · ownership.nature: Dr. Denner disclaims beneficial ownership of the shares being reported on this Form 4 except to the extent of his pecuniary interest therein. F2 · ownership.nature: Sarissa Capital Management LP ("Sarissa Capital") is the investment advisor to certain investment funds, including the funds that directly beneficially own the securities reported herein (the "Sarissa Funds"). Alexander Denner is the Chief Investment Officer of Sarissa Capital and controls the ultimate general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:08 UTC |
PANGIA ROBERT WDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,114 | Not disclosed Strike: $53.43 | Not disclosed |
DisclosureSEC source: 0001127602-19-012198 · form4.xml · derivative · entry 3 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,114 shares Expires 2019-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F3 · derivative.exercise_price: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d). F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · derivative.underlying_shares: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:08 UTC |
PANGIA ROBERT WDirector
|
SaleCommon Stock | 6,114 | $328.55 | $2,008,754.70 |
DisclosureSEC source: 0001127602-19-012198 · form4.xml · nonDerivative · entry 2 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,587 F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:08 UTC |
PANGIA ROBERT WDirector
|
Exercise / conversionCommon Stock | 6,114 | $52.22 | $319,273.08 |
DisclosureSEC source: 0001127602-19-012198 · form4.xml · nonDerivative · entry 1 PANGIA ROBERT W · CIK 0001236188 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC |
McKenzie PaulEVP Pharmaceutical Oper & Tech
|
OtherRestricted Stock Unit · Derivative | 280 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · derivative · entry 5 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280 shares Expires 2019-03-01 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC |
McKenzie PaulEVP Pharmaceutical Oper & Tech
|
Exercise / conversionRestricted Stock Unit · Derivative | 568 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · derivative · entry 4 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280 Underlying: Common Stock · 568 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC |
McKenzie PaulEVP Pharmaceutical Oper & Tech
|
Tax withholdingCommon Stock | 253 | $334.10 | $84,527.30 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · nonDerivative · entry 3 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,234.631 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC |
McKenzie PaulEVP Pharmaceutical Oper & Tech
|
Exercise / conversionCommon Stock | 568 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · nonDerivative · entry 2 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,487.631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:17 UTC |
McKenzie PaulEVP Pharmaceutical Oper & Tech
|
Tax withholdingCommon Stock | 405 | $334.10 | $135,310.50 |
DisclosureSEC source: 0001127602-19-009924 · form4.xml · nonDerivative · entry 1 McKenzie Paul · CIK 0001677903 · EVP Pharmaceutical Oper & Tech 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,919.631 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 6,395 | Not disclosed Strike: $49.65 | Not disclosed |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · derivative · entry 7 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,395 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F1 · kind: The stock option was automatically exercised on a net share settlement basis immediately before its expiration, in accordance with its terms. The Company delivered to the reporting person the number of shares underlying the stock option less the number of shares having a Fair Market Value on the date of such exercise equal to (i) the aggregate exercise price for the stock option and (ii) the amount necessary to satisfy any federal, state and local withholding taxes related to such exercise. F2 · shares: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F5 · derivative.exercise_date: The stock options become exercisable in four (4) equal annual installments commencing one year after the grant date of 02/24/09. F2 · derivative.underlying_shares: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.
|
OtherRestricted Stock Unit · Derivative | 819 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · derivative · entry 6 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 819 shares Expires 2019-02-22 F4 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,663 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · derivative · entry 5 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819 Underlying: Common Stock · 1,663 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.
|
Tax withholdingCommon Stock | 739 | $325.33 | $240,418.87 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · nonDerivative · entry 4 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,976 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.
|
Tax withholdingCommon Stock | 3,370 | $325.33 | $1,096,362.10 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · nonDerivative · entry 3 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,715 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.
|
Exercise / conversionCommon Stock | 6,395 | $48.52 | $310,285.40 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · nonDerivative · entry 2 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The stock option was automatically exercised on a net share settlement basis immediately before its expiration, in accordance with its terms. The Company delivered to the reporting person the number of shares underlying the stock option less the number of shares having a Fair Market Value on the date of such exercise equal to (i) the aggregate exercise price for the stock option and (ii) the amount necessary to satisfy any federal, state and local withholding taxes related to such exercise. F2 · shares: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. F2 · price: This option was previously reported as covering 6,250 shares at an exercise price of $49.65 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:09 UTC |
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.
|
Exercise / conversionCommon Stock | 1,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008415 · form4.xml · nonDerivative · entry 1 ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC |
Sandrock AlfredEVP, Chief Medical Officer
|
OtherRestricted Stock Unit · Derivative | 819 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008414 · form4.xml · derivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 819 shares Expires 2019-02-22 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC |
Sandrock AlfredEVP, Chief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,663 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008414 · form4.xml · derivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819 Underlying: Common Stock · 1,663 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC |
Sandrock AlfredEVP, Chief Medical Officer
|
Tax withholdingCommon Stock | 739 | $325.33 | $240,418.87 |
DisclosureSEC source: 0001127602-19-008414 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,409.1941 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC |
Sandrock AlfredEVP, Chief Medical Officer
|
Exercise / conversionCommon Stock | 1,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008414 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,148.1941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:10 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
OtherRestricted Stock Unit · Derivative | 3,229 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007262 · form4.xml · derivative · entry 4 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,504 Underlying: Common Stock · 3,229 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:10 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,269 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007262 · form4.xml · derivative · entry 3 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,733 Underlying: Common Stock · 5,269 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:10 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 2,340 | $332.87 | $778,915.80 |
DisclosureSEC source: 0001127602-19-007262 · form4.xml · nonDerivative · entry 2 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,574.27 Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:10 UTC |
Vounatsos MichelDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 5,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007262 · form4.xml · nonDerivative · entry 1 Vounatsos Michel · CIK 0001672709 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,914.27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.